期刊文献+

阿仑膦酸钠对绝经后骨质疏松症患者骨代谢指标的影响 被引量:31

Effect of alendronate on bone turnover biomarkers in postmenopausal osteoporosis
下载PDF
导出
摘要 目的观察抗骨吸收药物双膦酸盐对绝经后骨质疏松症患者骨代谢状态的影响。方法本研究为回顾性研究,共收集在我院骨质疏松门诊数据库中临床资料完整的女性绝经后骨质疏松症患者152例,其中阿仑膦酸钠治疗组93例(A组),每周给予阿仑膦酸钠70 mg,一次口服;未服用阿仑膦酸钠对照组59例(B组)。分别观察治疗前和治疗后3、6、12个月骨转换生化指标:骨特异性碱性磷酸酶(BAP)、抗酒石酸酸性磷酸酶(TRAP-5b)及25羟维生素D(25(OH)VD)的变化。结果 A组患者经阿仑膦酸钠治疗3个月后BAP和TRAP-5b水平分别较治疗前下降30.60%和32.95%(P<0.001)治疗6个月时完全降至女性绝经前水平,并一直维持在此水平至治疗后12个月。B组患者治疗前后BAP和TRAP-5b水平差异无统计学意义。结论绝经后骨质疏松症患者骨代谢处于高转换状态,其BAP及TRAP-5b水平较绝经前明显升高;经阿仑膦酸钠治疗3个月后高转换状态可以明显改善,骨转换指标BAP和TRAP-5b水平回落到绝经前水平。 Objective To observe the effect of bisphosphonates ( Fosamax ) on bone turnover biomarkers in postmenopausal osteoporosis women.Methods A retrospective study was performed.A total of 152 postmenopausal osteoporosis women with complete clinical data, who were selected from the out-patients osteoporosis clinical database of our hospital, were divided into 2 groups:the alendronate treatment group (Group A, n=93) and the control group (Group B, n=59).Patients in Group A took an oral medication of 70mg alendronate tablets ( Fosamax) once a week.And patients in group B were treated without the medication of alendronate.The bone turnover biomarkers, including the changes of bone specific alkaline phosphatase ( BAP) , tartaric-resistant acid phosphatase (TRAP-5b), and 25-hydroxy vitamin D (25(OH)VD), were observed before the treatment and at the 3rd, the 6th, and 12th month after the treatment.Results After 3-month treatment, the serum levels of BAP and TRAP-5b in Group A decreased by 30.60% and 32.95%, respectively, compared with that before the treatment ( P &lt;0.001 ) , And after 6-month treatment, they totally fell back to the level similar to that in premenopausal women, and remained at this level until 12 months after the treatment.On the contrary, no significant difference of the serum levels of BAP and TRAP-5b before and after the treatment in Group B was observed.Conclusion The bone metabolism in postmenopausal osteoporosis patients is at a high turnover status, and the serum levels of BAP and TRAP-5b increased significantly compared to that in premenopausal women.After 3-month treatment with alendronate, the high turnover status can be significantly improved, and the levels of serum BAP and TRAP-5b can fall back to the premenopausal levels.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2014年第1期22-25,共4页 Chinese Journal of Osteoporosis
关键词 双膦酸盐 绝经后骨质疏松症 骨转换指标 骨特异性碱性磷酸酶(BAP) 抗酒石酸酸性磷酸酶(TRAP-5b) Bisphosphonate Postmenopausal osteoporosis Bone turnover biomarkers
  • 相关文献

参考文献8

  • 1Moon HJ,Kim TH,Byun DW. Positive Correlation between Erythrocyte Levels of n-3 Polyunsaturated Fatty Acids and Bone Mass in Postmenopausal Korean Women with Osteoporosis[J].{H}Annals of Nutrition and Metabolism,2012,(02):146-153. 被引量:1
  • 2Szulc P,Delmas PD. Biochemical markers of bone turnover:potential use in the investigation and management of postmenopausal osteoporosis[J].{H}Osteoporosis International,2008,(12):1683-1704. 被引量:1
  • 3Karpf DB,shapiro DR,Seeman F. prevention of nonvertebral fractures by alendronate:a meta-analysis[J].{H}JAMA:the Journal of the American Medical Association,1997,(14):1159-1164. 被引量:1
  • 4Kanis JA,Burle N,Cooper C. European guidance for the diagnosis and management of osteoporosis in post-menopausal women[J].{H}Osteoporosis International,2008.399-428. 被引量:1
  • 5Ebert R,Zeck S,Krug R. Pulse treatmeng with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation[J].{H}BONE,2009,(05):858-864. 被引量:1
  • 6Szulc P,Delmas PD. Biochemical markers of bone turnover:potential use in the investigation and management of postmenopausal osteoporosis[J].{H}Osteoporosis International,2008,(12):1683-1704. 被引量:1
  • 7Sebba A. Osteoporosis:how long should we treat[J].Curr Opin Endocrinol Diabetes Obes,2008,(06):502-507. 被引量:1
  • 8Black DM,Schwartz AV,Ensrud KE. Effects of continuing or stopping alendronate after 5 years of treatment:the Fracture Intervention Trial Long-term Extension (FLEX):a randomized trial[J].{H}JAMA:the Journal of the American Medical Association,2006,(24):2927-2938. 被引量:1

同被引文献489

引证文献31

二级引证文献452

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部